Actos (pioglitazone), a new "glitazone" for type 2 diabetes.
October 2000
Lilly is now marketing Actos (pioglitazone), a new "glitazone" for type 2 diabetes.
It's the second one to hit the market...after Avandia (rosiglitazone). Rezulin (troglitazone) was never marketed in Canada...and was pulled off the U.S. market due to liver toxicity.
Actos and Avandia lower blood glucose by improving insulin sensitivity.
Practical advice for a better career, with unlimited access to CE
Pharmacy Technician's Letter Canada includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 120+ CE courses, including the popular CE-in-the-Letter
- Helpful, in-depth Technician Tutorials
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote